{"id":"NCT02400346","sponsor":"H. Lundbeck A/S","briefTitle":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","officialTitle":"Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2016-06","completion":"2016-06","firstPosted":"2015-03-27","resultsPosted":"2017-06-26","lastUpdate":"2017-08-10"},"enrollment":132,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depression Disorder"],"interventions":[{"type":"DRUG","name":"Adjunct brexpiprazole","otherNames":[]},{"type":"DRUG","name":"ADT","otherNames":[]}],"arms":[{"label":"Adjunct brexpiprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment","primaryOutcome":{"measure":"Number of Patients With Treatment-Emergent Adverse Events","timeFrame":"Baseline to 30 weeks","effectByArm":[{"arm":"Adjunct Brexpiprazole","deltaMin":102,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":34,"countries":["United States","Estonia","Finland","Germany","Poland"]},"refs":{"pmids":["30039634"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":132},"commonTop":["Fatigue","Restlessness","Increased appetite","Weight increased","Akathisia"]}}